Logo image of SXTC

CHINA SXT PHARMACEUTICALS IN (SXTC) Stock Fundamental Analysis

NASDAQ:SXTC - Nasdaq - VGG2161P1577 - Common Stock - Currency: USD

1.88  +0.02 (+1.08%)

Fundamental Rating

3

Overall SXTC gets a fundamental rating of 3 out of 10. We evaluated SXTC against 195 industry peers in the Pharmaceuticals industry. SXTC has a medium profitability rating, but doesn't score so well on its financial health evaluation. SXTC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

SXTC had positive earnings in the past year.
SXTC had a negative operating cash flow in the past year.
In the past 5 years SXTC always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: SXTC reported negative operating cash flow in multiple years.
SXTC Yearly Net Income VS EBIT VS OCF VS FCFSXTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of SXTC (18.70%) is better than 98.46% of its industry peers.
With an excellent Return On Equity value of 38.54%, SXTC belongs to the best of the industry, outperforming 97.44% of the companies in the same industry.
SXTC's Return On Invested Capital of 30.29% is amongst the best of the industry. SXTC outperforms 98.46% of its industry peers.
Industry RankSector Rank
ROA 18.7%
ROE 38.54%
ROIC 30.29%
ROA(3y)-16.86%
ROA(5y)-21.19%
ROE(3y)-32.52%
ROE(5y)-44.85%
ROIC(3y)N/A
ROIC(5y)N/A
SXTC Yearly ROA, ROE, ROICSXTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

The Profit Margin of SXTC (318.69%) is better than 99.49% of its industry peers.
SXTC has a better Operating Margin (340.71%) than 100.00% of its industry peers.
SXTC has a Gross Margin (22.02%) which is in line with its industry peers.
SXTC's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 340.71%
PM (TTM) 318.69%
GM 22.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.51%
GM growth 5Y-15.27%
SXTC Yearly Profit, Operating, Gross MarginsSXTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

3

2. Health

2.1 Basic Checks

SXTC has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, SXTC has more shares outstanding
The number of shares outstanding for SXTC has been increased compared to 5 years ago.
The debt/assets ratio for SXTC has been reduced compared to a year ago.
SXTC Yearly Shares OutstandingSXTC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50K 100K 150K 200K 250K
SXTC Yearly Total Debt VS Total AssetsSXTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

SXTC has an Altman-Z score of 0.95. This is a bad value and indicates that SXTC is not financially healthy and even has some risk of bankruptcy.
SXTC's Altman-Z score of 0.95 is in line compared to the rest of the industry. SXTC outperforms 59.49% of its industry peers.
SXTC has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.06, SXTC perfoms like the industry average, outperforming 52.31% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 0.95
ROIC/WACC3.75
WACC8.08%
SXTC Yearly LT Debt VS Equity VS FCFSXTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M

2.3 Liquidity

SXTC has a Current Ratio of 1.40. This is a normal value and indicates that SXTC is financially healthy and should not expect problems in meeting its short term obligations.
SXTC's Current ratio of 1.40 is on the low side compared to the rest of the industry. SXTC is outperformed by 71.28% of its industry peers.
SXTC has a Quick Ratio of 1.35. This is a normal value and indicates that SXTC is financially healthy and should not expect problems in meeting its short term obligations.
SXTC's Quick ratio of 1.35 is on the low side compared to the rest of the industry. SXTC is outperformed by 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.35
SXTC Yearly Current Assets VS Current LiabilitesSXTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 117.22% over the past year.
The Revenue has been growing slightly by 6.99% in the past year.
SXTC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -22.75% yearly.
EPS 1Y (TTM)117.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.72%
Revenue 1Y (TTM)6.99%
Revenue growth 3Y-26.11%
Revenue growth 5Y-22.75%
Sales Q2Q%-11.72%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SXTC Yearly Revenue VS EstimatesSXTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 0.05, the valuation of SXTC can be described as very cheap.
SXTC's Price/Earnings ratio is rather cheap when compared to the industry. SXTC is cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.32. SXTC is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 0.05
Fwd PE N/A
SXTC Price Earnings VS Forward Price EarningsSXTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, SXTC is valued cheaply inside the industry as 98.97% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.05
SXTC Per share dataSXTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SXTC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHINA SXT PHARMACEUTICALS IN

NASDAQ:SXTC (6/18/2025, 10:24:33 AM)

1.88

+0.02 (+1.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.03%
Inst Owner Change136.35%
Ins Owners0.11%
Ins Owner ChangeN/A
Market Cap30.51M
Analysts0
Price TargetN/A
Short Float %0.85%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.05
Fwd PE N/A
P/S 16.78
P/FCF N/A
P/OCF N/A
P/B 2.03
P/tB 2.03
EV/EBITDA 2.05
EPS(TTM)40.81
EY2170.74%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0.11
BVpS0.93
TBVpS0.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 18.7%
ROE 38.54%
ROCE 40.41%
ROIC 30.29%
ROICexc N/A
ROICexgc N/A
OM 340.71%
PM (TTM) 318.69%
GM 22.02%
FCFM N/A
ROA(3y)-16.86%
ROA(5y)-21.19%
ROE(3y)-32.52%
ROE(5y)-44.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.51%
GM growth 5Y-15.27%
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA 0.15
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 164.77
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.4
Quick Ratio 1.35
Altman-Z 0.95
F-Score3
WACC8.08%
ROIC/WACC3.75
Cap/Depr(3y)16.75%
Cap/Depr(5y)40.04%
Cap/Sales(3y)2.08%
Cap/Sales(5y)3.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)117.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.72%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)6.99%
Revenue growth 3Y-26.11%
Revenue growth 5Y-22.75%
Sales Q2Q%-11.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y144.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-8942.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9119%
OCF growth 3YN/A
OCF growth 5YN/A